CSPC Pharmaceutical Group... (CSPCY)
OTC: CSPCY
· Real-Time Price · USD
5.56
0.15 (2.77%)
At close: Aug 15, 2025, 3:58 PM
5.41
-2.70%
After-hours: Aug 13, 2025, 08:00 PM EDT
CSPC Pharmaceutical Balance Sheet Statement
Financials in CNY. Fiscal
year is
January - December.
| Fiscal Year | Q4 2024 | Q2 2024 | Q4 2023 | Q2 2023 | Q4 2022 | Q2 2022 | Q4 2021 | Q2 2021 |
| Period Ending | Dec 31, 2024 | Jun 30, 2024 | Dec 31, 2023 | Jun 30, 2023 | Dec 31, 2022 | Jun 30, 2022 | Dec 31, 2021 | Jun 30, 2021 |
Cash & Equivalents | 6.78B | 8.37B | 11.98B | 10.47B | 10.15B | 9.07B | 11.36B | 9.72B |
Short-Term Investments | 1.47B | 2.44B | 1.07B | 1.63B | 3.52B | 4.35B | 1.77B | 3.59B |
Long-Term Investments | 4.8B | 6.44B | 4.64B | 3.03B | 3.73B | 3.36B | 4.42B | 4.24B |
Other Long-Term Assets | 1.53B | 50.67M | 222.58M | 2.25B | 553.73M | 551.87M | 513.63M | 237.43M |
Receivables | 9.94B | 11.91B | 9.68B | 9.48B | 6.69B | 5.99B | 7.98B | 6.93B |
Inventory | 3.13B | 3.46B | 3.13B | 2.75B | 2.52B | 2.63B | 3.03B | 2.2B |
Other Current Assets | 362.35M | 742.58M | 9.52B | 9.54B | 6B | 5.32B | 6.55B | 5.8B |
Total Current Assets | 21.89B | 26.45B | 26.67B | 24.38B | 23.62B | 22.84B | 24.88B | 22.98B |
Property-Plant & Equipment | 13.08B | 12.23B | 12.23B | 11.36B | 10.82B | 10.08B | 11.7B | 11.02B |
Goodwill & Intangibles | 2.84B | 2.47B | 2.2B | 2.5B | 2.34B | 1.91B | 939.25M | 912.58M |
Total Long-Term Assets | 22.5B | 21.42B | 19.48B | 19.29B | 17.56B | 16.02B | 17.62B | 16.51B |
Total Assets | 44.39B | 47.87B | 46.15B | 43.67B | 41.18B | 38.85B | 42.5B | 39.48B |
Account Payables | 2.61B | 3.23B | 2.57B | 2.36B | 1.77B | 1.53B | 1.62B | 1.48B |
Deferred Revenue | n/a | -6.63B | 325.24M | 251.91M | 788.16M | 255.17M | 524.05M | 395.42M |
Short-Term Debt | 392.2M | 202.46M | 407.7M | 55.37M | 291.38M | 328.21M | n/a | n/a |
Other Current Liabilities | 945.86M | 245.2M | 1.38B | 233.51M | 1.63B | 1.46B | 2.26B | 1.73B |
Total Current Liabilities | 9.63B | 10.43B | 10.15B | 9.03B | 8.83B | 8.46B | 8.84B | 8.32B |
Long-Term Debt | n/a | n/a | n/a | 19.9M | 25.42M | 10.06M | n/a | n/a |
Other Long-Term Liabilities | 407.81M | 922.38M | 121.35M | 372.32M | 96.89M | 348.72M | 97.59M | 330.79M |
Total Long-Term Liabilities | 888.67M | 988.7M | 738.86M | 1.14B | 886.28M | 964.48M | 534.69M | 750.51M |
Total Liabilities | 10.52B | 11.42B | 10.89B | 10.16B | 9.72B | 9.43B | 9.37B | 9.07B |
Total Debt | 507.33M | 388.87M | 704.81M | 415.26M | 574.32M | 682.81M | 115.04M | 185.7M |
Common Stock | 11.03B | 11.01B | 10.87B | 10.9B | 10.75B | 10.9B | 13.33B | 13.1B |
Retained Earnings | 23.34B | 25.03B | 21.77B | 22.86B | 20.84B | 19.2B | 21.13B | 18.87B |
Comprehensive Income | n/a | n/a | -1.41B | -1.73B | -1.73B | -1.96B | -2.57B | -2.4B |
Shareholders Equity | 32.26B | 34.83B | 33.1B | 31.82B | 29.77B | 28.05B | 31.79B | 29.45B |
Total Investments | 6.27B | 8.88B | 5.72B | 4.66B | 7.25B | 7.7B | 6.18B | 7.82B |